|
KMID : 1100120190260010039
|
|
대한골대사학회지
2019 Volume.26 No. 1 p.39 ~ p.44
|
|
|
Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration
|
|
Park Chan-Ho
Jung Ki-Jin
Nho Jae-Hwi
Kim Ja-Hyung
Won Sung-Hun
Chun Dong-Il
Byun Dong-Won
|
|
|
Abstract
|
|
|
Background: Bisphosphonate (BP) is an effective drug for the prevention and treatment of osteoporosis. However, gastrointestinal distress caused by BP is a well-known side effect for low compliance. The aim of our study was to compare the 1-year persistence, compliance and T-scores between the aperitif medication group and the postprandial medication group.
Methods: Three hundred patients were included in this study to determine their persistence and compliance with the prescribed daily BP (Maxmarvil®, alendronate 5 mg and calcitriol 0.5 μg; YuYu Pharm) following distal radius fractures. Patients in Group 1 (aperitif medication) were asked to adhere to the general guidelines for BPs before breakfast. Patients in Group 2 (postprandial medication) were recommended medication after breakfast. We compared the persistence and compliance of this daily BP therapy using the medication possession ratio (MPR) and T-scores between the 2 groups after 1 year.
Results: Bone mineral density in hip and lumbar spine was improved significantly in 2 groups (P<0.001). Significant differences existed between 2 groups, including 73 of 150 patients (48.7%) in Group 1, and 111 of 150 patients (73.3%) in Group 2 for 1-year persistence (P=0.001). The mean MPR is 0.66 in Group 1 (range, 0.50?0.86) and 0.71 in Group 2 (range, 0.54?0.87). A significant difference was detected between the 2 groups (P=0.002).
Conclusions: Postprandial administration improved persistence and compliance with daily BP therapy, resulting in better clinical outcomes.
|
|
|
KEYWORD
|
|
|
Aperitif, Bisphosphonate, Compliance, Daily, Persistence, Postprandial
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|